Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MHH and Rentschler Sign Licensing Agreement for an Innovative Gene Therapy Vector System

25.07.2012
Ascenion assists the project from patenting to commercialization

The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop packaging cell lines containing the novel vector and to use these commercially for the contract manufacturing of gene therapeutics.

Scientists at the MHH previously showed that the vector system can be flexibly adapted to various applications and is produced efficiently in cell lines normally used in the production of biopharmaceuticals. Ascenion, the MHH’s exclusive technology transfer partner, facilitated the commercialization of the invention, from the patent application to forging the cooperation and negotiating the licensing agreement.

The MHH vector represents an advancement over conventional vector systems, whose therapeutic efficacy has already been established in many indications. “We have created a new platform with broad applications in gene therapy that offers improved safety to patients and increased cost-effectiveness to developers and healthcare systems,” says Prof. Christopher Baum, Director of the Institute for Experimental Haematology at the MHH. Prof. Baum developed the vector system together with his colleagues Dr Julia Sürth and Dr Dr Axel Schambach, supported in part by funding from the Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence REBIRTH (from Regenerative Biology to Reconstructive Therapy).

The main areas of application range from introducing therapeutic genes into blood stem cells and lymphocytes in order to correct congenital defects, to improving cellular immunity in cancer and HIV infection. Further cell types and diseases are also being targeted using the new vector system.

Prof. Roland Wagner, Senior Vice President Development at Rentschler Biotechnologie GmbH, emphasizes: “The new vector system complements our spectrum for the development of virus-based biologics used in gene therapy and virotherapy, which, beside Rentschler’s own AAV vector technology, will be made available to our clients for the development of these products.” Rentschler is currently financing further research at the MHH on highly efficient and stable packaging cell lines for retroviral vectors.

Ascenion will continue to assist with the project. “We are delighted that the research findings from the MHH have been developed to the benefit of patients,” commented Dr Christian Stein, Ascenion’s CEO. “The partners complement each other perfectly: the MHH contributes its innovative technology and proximity to patients, and Rentschler contributes its longstanding experience in the production of biopharmaceuticals and its tight industry network.”

Contacts
Ascenion: Anja Kroke, Corporate Communications
T: +49 (0)89 318814-30, E: kroke@ascenion.de
Ascenion GmbH, Herzogstraße 64, 80803 Munich
MHH: Camilla Krause, Public Relations Cluster of Excellence REBIRTH
T: +49 (0)511 532-6793, E: pressestelle@mh-hannover.de
Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover
Rentschler Biotechnologie: Friederike Braun, Director Marketing
T: +49 (0)7392 701-478 , E: friederike.braun@rentschler.de
Rentschler Biotechnologie GmbH, Erwin-Rentschler-Str. 21, 88471 Laupheim
About Ascenion GmbH
Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the Life-Science Foundation for the Promotion of Science and Research and has since acquired 23 research institutes in the Helmholtz and Leibniz Associations, together with the Hanover Medical School and the research institute Twincore as exclusive partners. Ascenion currently markets around 700 technologies on behalf of these institutes, and closes an average of about 70 agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 25 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hannover and Neuherberg.

Further information at www.ascenion.de

About the Hannover Medical School (MHH)

Hannover Medical School (MHH), founded in 1965, is one of Germany's leading universities in research, patient care and teaching. With its concentrated support of specialised research areas, it has become one of the best university clinics in the country. The outstanding research conducted at Germany's only institution of higher education exclusively devoted to medicine has been clearly recognised within the framework of the Excellence Initiative supported by the federal and state governments.

Further information at www.mh-hannover.de

About Rentschler

Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years’ experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1000 and 2500 liters, allowing the production of material for clinical trials (Phases I to III) and for market supply, and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.

Further information at www.rentschler.de

Stefan Zorn | idw
Further information:
http://www.mh-hannover.de
http://www.rentschler.de
http://www.ascenion.de

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Thanks for the memory: NIST takes a deep look at memristors

22.01.2018 | Materials Sciences

Radioactivity from oil and gas wastewater persists in Pennsylvania stream sediments

22.01.2018 | Earth Sciences

Saarland University bioinformaticians compute gene sequences inherited from each parent

22.01.2018 | Life Sciences

VideoLinks Wissenschaft & Forschung
Overview of more VideoLinks >>>